Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders... Show more
a provider of drug discovery and development services
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HERO | 27.26 | 0.63 | +2.38% |
| Global X Video Games & Esports ETF | |||
| NBIE | 27.15 | 0.27 | +1.00% |
| Neuberger International Core Equity ETF | |||
| DIVG | 37.80 | 0.33 | +0.88% |
| Invesco S&P 500 Hi Div Grwrs ETF | |||
| TLT | 80.87 | 0.09 | +0.11% |
| iShares 20+ Year Treasury Bond ETF | |||
| KORP | 45.25 | 0.01 | +0.02% |
| American Century Dvrs Corp Bd ETF | |||
A.I.dvisor indicates that over the last year, XENE has been loosely correlated with RLMD. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then RLMD could also see price increases.
| Ticker / NAME | Correlation To XENE | 1D Price Change % | ||
|---|---|---|---|---|
| XENE | 100% | -0.26% | ||
| RLMD - XENE | 55% Loosely correlated | +11.06% | ||
| ANTX - XENE | 46% Loosely correlated | -4.92% | ||
| MLTX - XENE | 44% Loosely correlated | -5.08% | ||
| DNTH - XENE | 43% Loosely correlated | +2.83% | ||
| REPL - XENE | 42% Loosely correlated | -2.42% | ||
More | ||||
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Following a +0.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where XENE advanced for three days, in 201 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
XENE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XENE as a result. In 75 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
XENE moved below its 50-day moving average on August 27, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XENE crossed bearishly below the 50-day moving average on August 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XENE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
The Aroon Indicator for XENE entered a downward trend on September 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. XENE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.572) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (588.235) is also within normal values, averaging (427.627).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.